A kind of non-integrated listeria vaccine and anti-tumor immune response method

Abstract

The present disclosure relates to a non-integrated Listeria vaccine and anti-tumor immune response method. Specifically, the present disclosure relates to a recombinant nucleic acid molecule, a recombinant plasmid or a recombinant expression vector containing the recombinant nucleic acid molecule, a recombinant protein, and a recombinant Listeria. At the same time, the disclosure also relates to pharmaceutical compositions, vaccines and applications containing the above components, and further provides a method for slowly and persistently killing cells and a method for inducing an immune response in a subject. The plasmids employed in the present disclosure are very stable over multiple passages of Listeria. The vector obtained in the present disclosure can not be affected by the enzyme cleavage site on the heterologous antigen, is convenient to operate, has high insertion efficiency and accurate insertion, and greatly improves the expression of the non-integrated Listeria tumor vaccine antigen peptide, making it suitable for use in The effect on the anti-tumor immune response is more significant.

Description

technical field [0001] The present disclosure relates primarily to the field of biotechnology. Specifically, the present disclosure provides a non-integrated attenuated Listeria tumor or cancer vaccine, a method of increasing the expression of an antigenic peptide against a tumor or cancer, and a method of increasing an immune response against a tumor or cancer. Background technique [0002] Listeria monocytogenes (Listeria monocytogenes, Lm) is an important food-borne pathogen, which widely exists in fresh or ready-to-eat foods, and may cause severe Listeria infection to the elderly, children, pregnant women and immunosuppressed people. fungal disease. Listeria is a Gram-positive intracellular parasite that can survive and multiply in epithelial cells and phagocytes. In different stages of parasitism and reproduction, Lm has multiple virulence factors to assist it in the infection of the body and then play a pathogenic role. At present, many factors related to the pathoge...

AI Technical Summary

Problems solved by technology

Alternatively, exogenous antigens can also be site-specifically integrated into non-essential regions of the LM genome (comK or tRNA Arg gene fragments) using the integrative vector pPL1 or pPL2, but this method requires antibiotics to maintain the strain selection[4]

[0006] To sum up, the listeria vaccines in the prior art are mainly expressed by integrating the antigen gene into the chromosome through homologous recombination. Although this method can avoid the introduction of new resistance genes, it has a long construction cycle and an integrated screening process. Complicated and other disadvantages

Although the non-integrated Listeria vaccine has the advantages of shorter construction cycle and simpler operation compared with the integrated Listeria vaccine, there are problems with the expression of antigenic peptides and expression stability, resulting in the use of the above method to construct Listeria. Vaccines have problems such as poor efficacy

Images